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Objective: To determine whether there were differences in depressed mood between overweight/obese men with
and without type 2 diabetes (T2DM) and to examine any associations between depressed mood, physical
functioning, and glycaemic control in overweight/obese men with and without T2DM.
Methods: Fifty seven overweight/obese men with (n = 19, age = 54.2 ± 7.4 yrs, BMI = 32.3 ± 6.7 kg⋅m-2) and without
T2DM (n = 38, age = 51.1 ± 6.8 yrs, BMI = 29.9 ± 4.5kg⋅m-2, p > 0.05 between groups) participated. The men
completed measures of depressed mood and health-related quality of life (HRQL) and underwent the following
assessments: fasting blood lipids and glucose, HbA1c, anthropometric measurements, VO2peak, muscle strength, and
physical function.
Results: Compared to men without T2DM, men with T2DM had higher depressed mood (p = 0.05, η2 = 0.07), as
well as lower perceived general health (p < .01, η2 = 0.24) and social functioning (p = .01, η2 = 0.10). Men with T2DM
also had lower VO2peak (21.8 ± 5.3 versus 25.8 ± 5.4 ml⋅kg
-1⋅min-1, p < .01, η2 = 0.11) and muscle strength (3.3 ± 0.8
versus 3.7 ± 0.7 kg⋅kg-1, p = 0.08, η2 = 0.06), as well as being slower to complete physical performance tasks (27.2 ±
5.2 versus 24.2 ± 2.8 sec, p < 0.01, η2 = 0.13). In those with T2DM, depressed mood was highly correlated with most
HRQL subscales. For the combined cohort, depressed mood was correlated with fasting glucose (r = 0.31, p = 0.012)
but not the functional measures.
Conclusions: Men with T2DM have higher levels of depressed mood compared to men without T2DM. Glycaemic
control, but not functional capacities, is associated with depressed mood in the study cohort.
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Most people with type 2 diabetes (T2DM) are over-
weight or obese [1] and, compared to people without
diabetes, have double the risk for depression [2]. Aside
from experiencing poor health, people with T2DM have
higher incidence of functional limitations, particularly if
they have poor glycaemic control [3].
The relationship between diabetes and depression is
bidirectional [4,5]. Up to a point, the severity of either* Correspondence: itamar.levinger@vu.edu.au
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reproduction in any medium, provided the orcondition seems to be associated with the chronicity of
the other. For example, in community-dwelling older
adults, depressive symptoms and HbA1c levels rise in
tandem until HbA1c levels reach about 8%, beyond
which the severity of both conditions plateau [6].
Although behavioural (e.g. diet, exercise), neurological
(activation of the hypothalamic-pituitary-adrenal and
sympathoadrenal systems), and pharmacological factors
have been suggested to contribute to the incidence of
T2DM among people with depression, evidence suggests
that the relationship between T2DM and depression is
maintained when these factors are taken into account
[4]. Similarly, other factors that have been hypothesised
to increase the incidence of depressive symptoms among
people with T2DM (e.g. presence of comorbidies andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tially influence the relationship between T2DM and de-
pression [4,7,8]. Further exploration of biological factors
may be warranted.
Associations between diabetes and physical function
have been established using objective measures (e.g. ac-
tivities of daily living, ADL) [9]. Being able to maintain
an active lifestyle is important for preserving or improv-
ing clinical status [10,11] and health related quality of
life (HRQL) [12] for people with diabetes. As people
with diabetes age, maintenance of ADLs takes on greater
significance, because deterioration of ADLs is associated
with loss of independence and increased risks of mor-
bidity and mortality [13]. The relationship between
physical function and HbA1c levels in people with
T2DM is unclear [3,13,14]. Some studies suggest that
higher HbA1c levels are associated with impaired phys-
ical function [3,13], whilst other research found no evi-
dence of this [14].
Compared to people without T2DM, people with
T2DM have lower aerobic capacity [15,16] as well as
longer time to recover from exercise [17] and lower mus-
cular strength [18,19]. Maintaining muscular strength is
important for reducing the likelihood of functional
limitations [20]. Being overweight or obese, as well as
having T2DM, may make exercise more challenging,
which may contribute further to loss of muscular
strength and functional decline, and the cycle repeats
itself.
Depression is associated with lower levels of physical
[21] and social functioning [22] in people with chronic
disease. In people with T2DM, the presence of complica-
tions (i.e. diabetic retinopathy, diabetic angiopathy and
diabetic neuropathy) has been associated with higher
prevalence and severity of both depression and func-
tional disability (indicating lower levels of physical func-
tion) [23]. Further, people with poor self-perceived
weight control had more depressive symptoms and
lower physical functioning, and that self-perceived
weight control was linearly related to BMI [23].
People with diabetes and co-morbid depression experi-
ence diminished HRQL [24,25]. Although relationships
are thought to exist between depression and mental
health components of HRQL in people with diabetes,
the relationship between depression and physical func-
tioning is not clear [24].
Evidence suggests that men and women may experi-
ence different levels of depression associated with T2DM
[26]. In this study, we focused on the experiences of
middle-aged men to exclude the potential effects of
menopause (metabolism and psychological). The aims of
the current study were (a) to determine whether there
were differences in depressed mood between over-
weight/obese men with and without T2DM and (b) toexamine the associations between depressed mood, func-
tional measures and glycaemic control in men with and
without T2DM. We hypothesized that patients with
T2DM have higher depressed mood and that depressed
mood would be correlated with impairment of physical
function and poorer glycaemic control.
Methods
Participants
Inclusion criteria: males with and without T2DM ≥40 yr
not participating in regular aerobic or resistance exercise
for the previous six months; Exclusion criteria: symp-
tomatic cardiovascular disease or musculoskeletal condi-
tions that impaired physical activity. Participants were
overweight or obese men with (n = 19) or without
(n = 38) T2DM (Table 1). Participants were on a range
of medications (Table 1).
The Victoria University and Austin Health Human Re-
search Ethics Committees approved the study protocol.
The participants provided informed consent before be-
coming involved with the study.
Measures
Demographics
Participants were asked to provide their ages, what med-
ications they were taking, and for those with T2DM, the
known duration of the disease.
Blood measures
A blood sample was collected after overnight fasting.
Blood was analysed (SYNCHRON LXW System/Lxi725,
Beckman Coulter Inc, CA, USA) for triglyceride (Trig),
high-density lipoprotein (HDL), glucose, and HbA1c.
Blood pressure
Blood pressure was measured using a mercury sphygmo-
manometer, as has been described previously [27].
Anthropometric measurements
Height was measured with participants standing barefoot
on a stadiometer (±0.5 cm). Weight was measured with
participants wearing just underwear while standing on a
calibrated scale (August Sauter GmbH, Germany)
(±0.05 kg).
Aerobic power
The full protocol for measuring aerobic power has been
described previously [27]. In brief, aerobic power
(VO2peak) was assessed using a sign and symptom lim-
ited graded exercise test on Cybex MET 100 cycle
(Cybex Metabolic Systems, Ronkonkoma, NY, USA).
VO2 for each 15 sec interval was measured by gas ana-
lysis (Medgraphics, Cardio2 and CPX/D System with
Breezeex Software, 142090–001, Revia, MN, USA).
Table 1 Comparison between overweight/obese men without diabetes (n = 38) and overweight/obese men with
diabetes (n = 19) on demographics and medications
Men without Diabetes Men with Diabetes η2 p
Demographics ————— ————— ————— —————
Age (yrs) 51.1 ± 6.8 54.2 ± 7.4 .04 .12
Height (cm) 175.9 ± 6.7 175.9 ± 5.8 .00 .99
Mass (kg) 92.4 ± 14.0 100.2 ± 23.0 .04 .12
BMI (kg⋅m-2) 29.9 ± 4.5 32.3 ± 6.7 .04 .12
Fasting Glucose (mmol · L-1) 5.4 ± 0.5 8.1 ± 1.9 .54 <.01*
HbA1c (%) 5.5 ± 0.3 6.8 ± 0.9 .51 <.01*
HbA1c (mmol · mol-1) 37 ± 4 50 ± 10 .51 <.01*
Trig (mmol · L-1) 1.5 ± 0.9 1.7 ± 0.8 .02 .35
HDL (mmol · L-1) 1.2 ± 0.4 1.0 ± 0.2 .08 .04*
SBP (mmHg) 130.0 ± 14.3 133.7 ± 16.4 .01 .38
DBP (mmHg) 86.6 ± 11.0 86.2 ± 13.3 .00 .90
Known duration of T2DM (yrs) ————— 2.5 ± 3.6 ————— —————
Medications ————— ————— ————— —————
Calcium channel blockers 0 3 ————— —————
ACE inhibitors 5 4 ————— —————
Beta-blockers 2 3 ————— —————
Cholesterol lowering medication 2 11 ————— —————
Glucose lowering medication 0 12 ————— —————
Angiotensin II receptor antagonist 1 4 ————— —————
Platelet inhibitor 0 2 ————— —————
Anti-depressants 2 3 ————— —————
Aspirin 0 6 ————— —————
*p < .05. BMI (body mass index), HbA1c (glycosylated-haemoglobin), Trig (triglyceride), HDL (high density lipoprotein), SBP (systolic blood pressure), DBP (diastolic
blood pressure). Data are mean ± SD.
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The Physical Performance Test (PPT) was used as an
objective measure of physical function. The full protocol
of the PPT has been described previously [27]. In brief,
the PPT included four functional mobility tasks, includ-
ing a 15 meters rapid walking test; a timed up-and-go
test where participants were required to rise from a
standard chair, walk 3 meters, and return to a seated
position on the chair; and stair climbing and stair des-
cending tests. All tests were timed (sec). The PPT score
was the sum of the fastest times for each of the four
tests.
Muscular strength
Muscular strength was evaluated using the one repeti-
tion maximum method for chest press and leg press, as
described previously [27]. Muscle strength was calcu-
lated as the sum of weight lifted in the two exercises,
and is expressed as relative to body mass.
Depressed mood
The Cardiac Depression Scale (CDS) was used as a meas-
ure of depressed mood in this populations as manypeople with T2DM also experience co-morbid cardiovas-
cular disease or are at a high risk of developing cardiovas-
cular disease The CDS contains 26 items, to which
participants responded on a 7-point Likert scale [28].
Higher scores are indicative of more severely depressed
mood. Scores ≥95 may be indicative of major depression
[29]. The CDS is a reliable tool to assess depressive symp-
toms in people at a high risk of developing T2DM with a
Cronbach’s alpha =0.84 and is sensitive for changes in de-
pressive symptoms post-exercise training [30].
Health-related quality of life
The SF-36 [31] was used to measure HRQL. This instru-
ment has eight subscales: physical functioning, role lim-
itations-physical, role limitations-emotional, energy/
fatigue, emotional well-being, social functioning, pain,
and general health. The SF36 is well accepted and one of
the most used questionnaires to assess HRQL in many
clinical and healthy populations
Statistical analyses
Where appropriate, data are reported as mean ± stand-
ard deviation (SD). An analysis of variance (ANOVA)
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between men with and without T2DM with respect to
their scores on the measures of physical function,
HRQL, depressed mood, aerobic power, and muscular
strength. In addition to statistical significance, effect
sizes for the difference between the two conditions, in
the form of η2, were calculated. η2 values provide the
proportion of variability in a dependent variable that can
be explained by the independent variable. Although η2
values for differences on physical measures vary widely
(i.e., between 0 and 1), on social and psychological mea-
sures (e.g., depression, HRQL) small, medium, and large
effects are 0.01, 0.06, and 0.14, respectively [32]. Pear-
son’s product moment correlations were calculated to
investigate the relationships between depressed mood
and functional measures, HRQL, and glycaemic control.
Although correlation coefficients (r) can vary widely
when physical measures are being correlated (between −1
and 1), on social and psychological measures small,
medium, and large effects are 0.1, 0.3, and 0.5,
respectively [32].
All statistical analyses were conducted at the 95% level
of significance and data reported as mean ± standard de-
viation (SD).
Results
Men with T2DM had higher fasting glucose and HbA1c
levels, and slightly lower HDL levels, compared to those
without T2DM (Table 1). There were no significant
differences between men with and without T2DM; how-
ever, with respect to age, height, mass, BMI, triglycer-
ides, and systolic and diastolic blood pressure. Men with
T2DM performed the physical performance tasks moreTable 2 Comparison between overweight/obese men without




Physical performance (secs) 24.2 ± 2.8
Health-Related Quality of Life —————
Physical functioning 87.6 ± 12.0
Role limitations – physical 81.6 ± 32.2
Role limitations – emotional 88.6 ± 27.2
Energy/fatigue 62.4 ± 14.5
Emotional well-being 79.5 ± 11.9
Social functioning 91.6 ± 13.9
Pain 72.9 ± 21.9
General health 69.1 ± 17.0
Depressed mood 72.3 ± 20.1
Aerobic Power (VO2peak) 25.8 ± 5.4
Muscular Strength (kg · kg) 3.7 ± 0.7
*p < .05. Data are mean ± SD.slowly, reported poorer perceptions of their general
health and social functioning and higher levels of
depressed mood, and recorded lower aerobic power
(Table 2). Depressed mood was correlated with several
aspects of HRQL (general health, energy/fatigue, and
emotional well-being) in men with and without T2DM
(Table 3). For each group separately there were no sig-
nificant correlations between depressed mood and phys-
ical function, aerobic power, muscular strength, and
glycaemic control. However, in the entire cohort (pooled
data), depressed mood correlated with fasting glucose
(r = 0.31, p = 0.012) but not aerobic power, muscle
strength or the capacity to perform ADLs (data adjusted
for BMI). There was no correlation between depressed
mood and BMI (adjusted and not adjusted for fasting
glucose).
Discussion
This study showed that men with T2DM have higher
levels of depressed mood than those without T2DM.
T2DM explained 7% of the variance in depressed mood
scores, which is a moderately large effect for a psycho-
logical measure [32]. This finding supports previous
work [2,33] and suggests that clinicians need to be vigi-
lant for the presence of co-morbid symptoms of depres-
sion when treating men with T2DM. This is supported
by evidence that the relationship between diabetes and
depression is bidirectional [4,5].
Consistent with previous work that has evaluated aer-
obic capacity [15,16,19] and strength [18,19] for people
with T2DM, the present study showed that men with
T2DM had lower aerobic capacity and strength than
men without T2DM. In addition, men with T2DM haddiabetes (n = 38) and overweight/obese men with
of life, depressed mood, aerobic capacity, and muscular
Men with Diabetes η2 p
————— ————— —————
27.3 ± 5.2 .13 <.01*
————— ————— —————
82.1 ± 12.4 .05 .11
76.3 ± 33.8 .01 .57
82.4 ± 35.8 .01 .47
60.8 ± 14.5 .00 .70
76.0 ± 13.5 .02 .32
79.7 ± 21.3 .10 .01*
80.3 ± 18.0 .03 .21
49.3 ± 16.9 .24 <.01*
83.9 ± 21.1 .07 .05
21.8 ± 5.3 .11 <.01*
3.3 ± .8 .06 .08
Table 3 Relationships between depressed mood and physical function, health-related quality of life, aerobic power,
muscular strength, and glycaemic control in overweight and obese men with and without T2DM
Depressed Mood in Men without Diabetes Depressed Mood in Men with Diabetes
r p r p
Physical Function ————— ————— ————— —————
Physical performance .15 .18 -.07 .39
Health-Related Quality of Life ————— ————— ————— —————
Physical functioning -.40 <.01* -.35 .07
Role limitations – physical -.47 <.01* -.58 <.01*
Role limitations – emotional -.16 .17 -.54 <.01*
Energy/fatigue -.67 <.01* -.85 <.01*
Emotional well-being -.67 <.01* -.56 <.01*
Social functioning -.31 .03 -.80 <.01*
Pain -.38 <.01* -.67 <.01*
General health -.70 <.01* -.34 .08
Aerobic Power -.17 .16 .26 .15
Muscular Strength -.23 .08 .20 .21
Glycaemic Control .08 .33 -.04 .44
*p < .05.
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and self-perceived). Taken together, these findings em-
phasise the value for people with T2DM to undertake
regular physical activity.
In both men with and without T2DM, depressed
mood was strongly associated with subjective measures
of functioning (subscales of HRQL) but weakly related
to objective measures of functioning (physical perform-
ance, aerobic power, muscular strength). This finding
may mean that men with depressed mood may perceive
their physical functioning to be worse than is evidenced
through objective measures, particularly those with
T2DM. Such perceptions may lead to lower self-efficacy
and discourage people with T2DM from undertaking
regular exercise and physical activity that they are cap-
able of performing, which may, in turn, have detrimental
effects on clinical, functional and psychosocial wellbeing.
For this reason, an interventional study is warranted for
people with T2DM that aims to relieve symptoms of de-
pression and improve self-efficacy for exercise; outcome
measures could include effects on long term exercise
participation, physical functioning and HRQL.
Depressed mood was strongly correlated with social
functioning in men with T2DM. The relationship be-
tween depression and social function is often significant
and pervasive, but is frequently underappreciated [34].
As part of treatments for both T2DM and depression,
clinicians should enquire about the social lives of men
with diabetes and work with them to build on their rela-
tionships with others.In men with diabetes, a large correlation was also
found between depressed mood and pain. Although
causation cannot be determined from this study, it
seems likely that pain could exacerbate depressed mood
as it may limit a person’s physical functioning and will-
ingness to exercise. With at least one quarter of people
with diabetes affected by distal symmetric polyneurop-
athy [35], with which people often experience debilitat-
ing neuropathic pain, clinicians need to account for pain
as a cause for depressed mood in their patients.
There is evidence that for people with T2DM, depres-
sion is associated with increased insulin resistance and
poor glycaemic control, whilst the links between gly-
caemic control and functional capacities are weaker for
people with T2DM [36]. The current study supports this
finding. Fasting glucose, but not objective measures of
physical function, was correlated with depressed mood.
This may have important implications for the preven-
tion, and management of depression in this population.
It highlights that improvements in glycaemic control
may not only have significant clinical benefits, such as
reductions in diabetic complications [37], but may also
have psychological benefits, and vice-versa. The current
study has several potential limitations including the
cross-sectional nature of the study, a relative small sam-
ple size and that these findings may not generalize to
women or other demographic groups.
In conclusion, men with T2DM have higher levels of
depressed mood and lower functional capacity, as mea-
sured by both objective and subjective tools, compared
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cose levels are associated with increased depressive
symptoms.
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